Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;12(2):145–153. doi: 10.1111/j.1750-3639.2002.tb00429.x

Allelic Gain and Amplification on the Long Arm of Chromosome 17 in Anaplastic Meningiomas

Rainer Büschges 1, Koichi Ichimura 1, Ruthild G Weber 2, Guido Reifenberger 3, V Peter Collins 1,✉
PMCID: PMC8095877  PMID: 11958368

Abstract

Using comparative genomic hybridization (CGH) we have previously identified amplification at 17q21‐qter as a common aberration in anaplastic meningiomas but not in atypical or benign meningiomas (19). To define the amplified genomic region, we analyzed 44 meningeal tumors, including 7 benign meningiomas of World Health Organization (WHO) grade I, 19 atypical meningiomas (WHO grade II) and 18 anaplastic meningiomas (WHO grade III) at 46 chromosome 17 loci (including 42 17q loci). In line with the CGH data we found evidence of increased numbers of alleles on 17q. The incidence rose with malignancy grade, culminating at 61% (11 of 18 cases) in the anaplastic meningioma group. The majority of cases showing increased allele numbers had, on average, low‐level allelic gains (relative increase in allele dosage of 2‐ to 5‐fold). Amplification of alleles (defined here as an average relative increase in allele dosage of more than 5 times) was detected in 2 anaplastic meningiomas. The amplification patterns in these tumors defined a number of common regions of amplification/increased allele copy number, the best defined include one between D17S790 and D17S1607 and one between D17S1160 and PS6K. Real‐time PCR analysis of the PS6K candidate gene revealed no high‐level amplification despite this affecting adjacent loci. Our findings are fundamental for the identification of the gene(s) in 17q22‐q23 that is (are) the target(s) for increased copy number in anaplastic meningiomas and possibly other tumor types.

Full Text

The Full Text of this article is available as a PDF (485.5 KB).

References

  • 1. Bärlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A (1997) Increased copy number at 17q22‐q24 by CGH in breast cancer is due to high‐level amplification of two separate regions. Genes Chromosomes Cancer 20:372–376. [DOI] [PubMed] [Google Scholar]
  • 2. Cai DX, James CD, Scheithauer BW, Couch FJ, Perry A (2001) PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 115:213–218. [DOI] [PubMed] [Google Scholar]
  • 3. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD (1999) Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59: 1408–1411. [PubMed] [Google Scholar]
  • 4. Fink L, Seeger W, Ermert L, Hänze J, Stahl U, Grimminger F, Kummer W, Bohle RM (1998) Real‐time quantitative RT‐PCR after laser‐assisted cell picking. Nat Med 4: 1329–1333. [DOI] [PubMed] [Google Scholar]
  • 5. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF (2000) Loss of DAL‐1, a protein 4.1‐related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9: 1495–1500. [DOI] [PubMed] [Google Scholar]
  • 6. Hovens CM, Kaye AH (2001) The tumour suppressor protein NF2/merlin: the puzzle continues. J Clin Neurosci 8: 4–7. [DOI] [PubMed] [Google Scholar]
  • 7. Ichimura K, Schmidt EE, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065–1072. [PubMed] [Google Scholar]
  • 8. Khan J, Parsa NZ, Harada T, Meltzer PS, Carter NP (1998) Detection of gains and losses in 18 meningiomas by comparative genomic hybridization. Cancer Genet Cytogenet 103:95–100. [DOI] [PubMed] [Google Scholar]
  • 9. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ (2000) Meningiomas In: Pathology and genetics of tumors of the nervous system. World Health Organization classification of tumors. Kleihues P, Cavenee WK (eds.), pp 176–184, IARC Press, Lyon . [Google Scholar]
  • 10. Muleris M, Almeida A, Gerbault‐Seureau M, Malfoy B, Dutrillaux B. (1994) Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosomes Cancer 10: 160–170. [DOI] [PubMed] [Google Scholar]
  • 11. Orsetti B, Courjal F, Cuny M, Rodriguez C, and Theillet C (1999) 17q21‐q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 18:6262–6270. [DOI] [PubMed] [Google Scholar]
  • 12. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046–2056. [DOI] [PubMed] [Google Scholar]
  • 13. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH (2000) Merlin, DAL‐1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872–879. [DOI] [PubMed] [Google Scholar]
  • 14. Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J, Casey G (1997) Four regions of allelic imbalance on 17q12‐qter associated with high‐grade breast tumors. Genes Chromosomes Cancer 20:354–362. [PubMed] [Google Scholar]
  • 15. Ried T, Just KE, Holtgreve‐Grez H, du Manoir S, Speicher MR, Schrock E, Latham C, Blegen H, Zetterberg A, Cremer T, et al. (1995) Comparative genomic hybridization of formalin‐fixed, paraffin‐embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 55:5415–5423. [PubMed] [Google Scholar]
  • 16. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjöld M, Collins VP, Dumanski JP, Rouleau GA (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6: 180–184. [DOI] [PubMed] [Google Scholar]
  • 17. Ueki K, Wen‐Bin C, Narita Y, Asai A, Kirino T (1999) Tight association of loss of merlin ex‐pression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995–5998. [PubMed] [Google Scholar]
  • 18. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, Sato A, Inazawa J (2001) A novel amplification at 17q21‐q23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81:172–177. [DOI] [PubMed] [Google Scholar]
  • 19. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94: 14719–14724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Wellenreuther R, Waha A, Vogel Y, Lenartz D, Schramm J, Wiestler OD, von Deimling A (1997) Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 77:601–606. [PubMed] [Google Scholar]
  • 21. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ (2000) 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGMA1B genes. Cancer Res 60:5371–5375. [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES